|
1
|
Cascella M, Rajnik M, Aleem A, Dulebohn S
and Di Napoli R: Features, Evaluation, and Treatment of Coronavirus
(COVID-19). StatPearls. 2021.
|
|
2
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mousavizadeh L and Ghasemi S: Genotype and
phenotype of COVID-19: Their roles in pathogenesis. J Microbiol
Immunol Infect. 54:159–163. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wrapp D, Wang N, Corbett KS, Goldsmith JA,
Hsieh CL, Abiona O, Graham BS and McLellan JS: Cryo-EM structure of
the 2019-nCoV spike in the prefusion conformation. Science.
367:1260–1263. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Walls AC, Park YJ, Tortorici MA, Wall A,
McGuire AT and Veesler D: Structure, function, and antigenicity of
the SARS-CoV-2 spike glycoprotein. Cell. 181:281–292.e6. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jaimes JA, André NM, Chappie JS, Millet JK
and Whittaker GR: Phylogenetic analysis and structural modeling of
SARS-CoV-2 spike protein reveals an evolutionary distinct and
proteolytically sensitive activation loop. J Mol Biol.
432:3309–3325. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang S, Yang M, Hong Z, Zhang L, Huang Z,
Chen X, He S, Zhou Z, Zhou Z, Chen Q, et al: Crystal structure of
SARS-CoV-2 nucleocapsid protein RNA binding domain reveals
potential unique drug targeting sites. Acta Pharm Sin B.
10:1228–1238. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghaebi M, Osali A, Valizadeh H, Roshangar
L and Ahmadi M: Vaccine development and therapeutic design for
2019-nCoV/SARS-CoV-2: Challenges and chances. J Cell Physiol.
235:9098–9109. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Théry C, Witwer KW, Aikawa E, Alcaraz MJ,
Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F,
Atkin-Smith GK, et al: Minimal information for studies of
extracellular vesicles 2018 (MISEV2018): A position statement of
the International Society for Extracellular Vesicles and update of
the MISEV2014 guidelines. J Extracell Vesicles. 7:15357502018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kowal J, Tkach M and Théry C: Biogenesis
and secretion of exosomes. Curr Opin Cell Biol. 29:116–125. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Minciacchi VR, Freeman MR and Di Vizio D:
Extracellular vesicles in cancer: Exosomes, microvesicles and the
emerging role of large oncosomes. Semin Cell Dev Biol. 40:41–51.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi DS, Kim DK, Kim YK and Gho YS:
Proteomics, transcriptomics and lipidomics of exosomes and
ectosomes. Proteomics. 13:1554–1571. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Record M, Carayon K, Poirot M and
Silvente-Poirot S: Exosomes as new vesicular lipid transporters
involved in cell-cell communication and various pathophysiologies.
Biochim Biophys Acta. 1841:108–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Yu M and Tian W: Physiological
and pathological impact of exosomes of adipose tissue. Cell Prolif.
49:3–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yarana C and St Clair DK:
Chemotherapy-induced tissue injury: An insight into the role of
extracellular vesicles-mediated oxidative stress responses.
Antioxidants. 6:752017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng H, Zhan Y, Liu S, Lu J, Luo J, Feng
J and Fan S: The roles of tumor-derived exosomes in non-small cell
lung cancer and their clinical implications. J Exp Clin Cancer Res.
37:2262018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu B, Zhang X and Li X: Exosomes derived
from mesenchymal stem cells. Int J Mol Sci. 15:4142–4157. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Caby MP, Lankar D, Vincendeau-Scherrer C,
Raposo G and Bonnerot C: Exosomal-like vesicles are present in
human blood plasma. Int Immunol. 17:879–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zlotogorski-Hurvitz A, Dayan D, Chaushu G,
Korvala J, Salo T, Sormunen R and Vered M: Human saliva-derived
exosomes: Comparing methods of isolation. J Histochem Cytochem.
63:181–189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SJ, Kim JM, Kim J, Hur J, Park S, Kim
K, Shin HJ and Chwae YJ: Molecular mechanisms of biogenesis of
apoptotic exosome-like vesicles and their roles as
damage-associated molecular patterns. Proc Natl Acad Sci USA.
115:E11721–E11730. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weichand B, Weis N, Weigert A, Grossmann
N, Levkau B and Brüne B: Apoptotic cells enhance
sphingosine-1-phosphate receptor 1 dependent macrophage migration.
Eur J Immunol. 43:3306–3313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lorizate M, Sachsenheimer T, Glass B,
Habermann A, Gerl MJ, Kräusslich HG and Brügger B: Comparative
lipidomics analysis of HIV-1 particles and their producer cell
membrane in different cell lines. Cell Microbiol. 15:292–304. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lorizate M and Kräusslich HG: Role of
lipids in virus replication. Cold Spring Harb Perspect Biol.
3:a0048202011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dogrammatzis C, Waisner H and Kalamvoki M:
Cloaked viruses and viral factors in cutting edge exosome-based
therapies. Front Cell Dev Biol. 8:3762020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nainu F, Abidin RS, Bahar MA, Frediansyah
A, Emran TB, Rabaan AA, Dhama K and Harapan H: SARS-CoV-2
reinfection and implications for vaccine development. Hum Vaccin
Immunother. 16:3061–3073. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao X, Wu D, Ma X, Wang J, Hou W and
Zhang W: Exosomes as drug carriers for cancer therapy and
challenges regarding exosome uptake. Biomed Pharmacother.
128:1102372020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun D, Zhuang X, Xiang X, Liu Y, Zhang S,
Liu C, Barnes S, Grizzle W, Miller D and Zhang HG: A novel
nanoparticle drug delivery system: The anti-inflammatory activity
of curcumin is enhanced when encapsulated in exosomes. Mol Ther.
18:1606–1614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saleh AF, Lázaro-Ibáñez E, Forsgard MA,
Shatnyeva O, Osteikoetxea X, Karlsson F, Heath N, Ingelsten M, Rose
J, Harris J, et al: Extracellular vesicles induce minimal
hepatotoxicity and immunogenicity. Nanoscale. 11:6990–7001. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu X, Badawi M, Pomeroy S, Sutaria DS,
Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle K, et al:
Comprehensive toxicity and immunogenicity studies reveal minimal
effects in mice following sustained dosing of extracellular
vesicles derived from HEK293T cells. J Extracell Vesicles.
6:13247302017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Walker S, Busatto S, Pham A, Tian M, Suh
A, Carson K, Quintero A, Lafrence M, Malik H, Santana MX, et al:
Extracellular vesicle-based drug delivery systems for cancer
treatment. Theranostics. 9:8001–8017. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arvin AM, Fink K, Schmid MA, Cathcart A,
Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D and Virgin
HW: A perspective on potential antibody-dependent enhancement of
SARS-CoV-2. Nature. 584:353–363. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Greinacher A, Thiele T, Warkentin TE,
Weisser K, Kyrle PA and Eichinger S: Thrombotic thrombocytopenia
after ChAdOx1 nCov-19 vaccination. N Engl J Med. 384:2092–2101.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsai SJ, Guo C, Atai NA and Gould SJ:
Exosome-mediated mRNA delivery for SARS-CoV-2 vaccination. bioRxiv.
Nov 6–2021.(Epub ahead of print). doi:
10.1101/2020.11.06.371419.
|
|
35
|
Polak K, Greze N, Lachat M, Merle D,
Chiumento S, Bertrand-Gaday C, Trentin B and Mamoun R:
Extracellular vesicle-based vaccine platform displaying native
viral envelope proteins elicits a robust anti-SARS-CoV-2 response
in mice. bioRxiv. Oct 28–2020.(Epub ahead of print). doi:
org/10.1101/2020.10.28.357137.
|
|
36
|
Lewis ND, Sia CL, Kirwin K, Haupt S,
Mahimkar G, Zi T, Xu K, Dooley K, Jang SC, Choi B, et al: Exosome
surface display of IL12 results in tumor-retained pharmacology with
superior potency and limited systemic exposure compared with
recombinant IL12. Mol Cancer Ther. 20:523–534. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Garcia-Beltran WF, Lam EC, St Denis K,
Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory
DJ, Poznansky MC, et al: Multiple SARS-CoV-2 variants escape
neutralization by vaccine-induced humoral immunity. Cell.
184:2372–2383. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vabret N, Britton GJ, Gruber C, Hegde S,
Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, et al:
Sinai Immunology Review Project, Immunology of COVID-19: current
state of the science. Immunity. 52:910–941. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Niu L, Wittrock KN, Clabaugh GC,
Srivastava V and Cho MW: A structural landscape of neutralizing
sntibodies sgainst SARS-CoV-2 receptor binding fomain. Front
Immunol. 12:6479342021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Garcia-Beltran WF, Lam EC, Astudillo MG,
Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL,
Nitido AD, et al: COVID-19-neutralizing antibodies predict disease
severity and survival. Cell. 184:476–488. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Prompetchara E, Ketloy C, Tharakhet K,
Kaewpang P, Buranapraditkun S, Techawiwattanaboon T,
Sathean-Anan-Kun S, Pitakpolrat P, Watcharaplueksadee S, Phumiamorn
S, et al: DNA vaccine candidate encoding SARS-CoV-2 spike proteins
elicited potent humoral and Th1 cell-mediated immune responses in
mice. PLoS One. 16:e02480072021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Khoury DS, Cromer D, Reynaldi A, Schlub
TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA and
Davenport MP: Neutralizing antibody levels are highly predictive of
immune protection from symptomatic SARS-CoV-2 infection. Nat Med.
27:1205–1211. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Le Bert N, Tan AT, Kunasegaran K, Tham CY,
Hafezi M, Chia A, Chng MH, Lin M, Tan N, Linster M, et al:
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS,
and uninfected controls. Nature. 584:457–462. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Grifoni A, Weiskopf D, Ramirez SI, Mateus
J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L,
Jadi RS, et al: Targets of T cell responses to SARS-CoV-2
coronavirus in humans with COVID-19 disease and unexposed
individuals. Cell. 181:1489–1501.e15. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W
and Gao GF: T-cell immunity of SARS-CoV: Implications for vaccine
development against MERS-CoV. Antiviral Res. 137:82–92. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Grifoni A, Sidney J, Zhang Y, Scheuermann
RH, Peters B and Sette A: A sequence homology and bioinformatic
approach can predict candidate targets for immune responses to
SARS-CoV-2. Cell Host Microbe. 27:671–680.e2. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang ZY, Werner HC, Kong WP, Leung K,
Traggiai E, Lanzavecchia A and Nabel GJ: Evasion of antibody
neutralization in emerging severe acute respiratory syndrome
coronaviruses. Proc Natl Acad Sci USA. 102:797–801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau
H, Su ST, Chia JM, Ng P, Chiu KP, Lim L, et al: Comparative
full-length genome sequence analysis of 14 SARS coronavirus
isolates and common mutations associated with putative origins of
infection. Lancet. 361:1779–1785. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Holmes KV and Enjuanes L: Virology. The
SARS coronavirus: A postgenomic era. Science. 300:1377–1378. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rota PA, Oberste MS, Monroe SS, Nix WA,
Campagnoli R, Icenogle JP, Peñaranda S, Bankamp B, Maher K, Chen
MH, et al: Characterization of a novel coronavirus associated with
severe acute respiratory syndrome. Science. 300:1394–1399. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhu Y, Liu M, Zhao W, Zhang J, Zhang X,
Wang K, Gu C, Wu K, Li Y, Zheng C, et al: Isolation of virus from a
SARS patient and genome-wide analysis of genetic mutations related
to pathogenesis and epidemiology from 47 SARS-CoV isolates. Virus
Genes. 30:93–102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cong Y, Ulasli M, Schepers H, Mauthe M,
V'kovski P, Kriegenburg F, Thiel V, de Haan CAM and Reggiori F:
Nucleocapsid protein recruitment to replication-transcription
complexes plays a crucial role in coronaviral life cycle. J Virol.
94:e01925–e19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Leung DT, Tam FC, Ma CH, Chan PK, Cheung
JL, Niu H, Tam JS and Lim PL: Antibody response of patients with
severe acute respiratory syndrome (SARS) targets the viral
nucleocapsid. J Infect Dis. 190:379–386. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gao W, Tamin A, Soloff A, D'Aiuto L,
Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S and Gambotto A:
Effects of a SARS-associated coronavirus vaccine in monkeys.
Lancet. 362:1895–1896. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Okada M, Takemoto Y, Okuno Y, Hashimoto S,
Yoshida S, Fukunaga Y, Tanaka T, Kita Y, Kuwayama S and Muraki Y:
The development of vaccines against SARS corona virus in mice and
SCID-PBL/hu mice. Vaccine. 23:2269–2272. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ferretti AP, Kula T, Wang Y, Nguyen DMV,
Weinheimer A, Dunlap GS, Xu Q, Nabilsi N, Perullo CR, Cristofaro
AW, et al: Unbiased screens show CD8+ T cells of
COVID-19 patients recognize shared epitopes in SARS-CoV-2 that
largely reside outside the spike protein. Immunity.
53:1095–1107.e3. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zollner A, Watschinger C, Rössler A,
Farcet MR, Penner A, Böhm V, Kiechl SJ, Stampfel G, Hintenberger R,
Tilg H, et al: B and T cell response to SARS-CoV-2 vaccination in
health care professionals with and without previous COVID-19.
EBioMedicine. 70:1035392021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fields BN, Knipe DM and Howley PM: Fields
virology 6th edition Chapter 28. 825–858. 2013.
|
|
59
|
Ng OW, Chia A, Tan AT, Jadi RS, Leong HN,
Bertoletti A and Tan YJ: Memory T cell responses targeting the SARS
coronavirus persist up to 11 years post-infection. Vaccine.
34:2008–2014. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L,
Zhu Q, Zhang X, Zheng Y, Geng C, et al: Potent neutralizing
antibodies against SARS-CoV-2 identified by high-throughput
single-cell sequencing of convalescent patients' B cells. Cell.
182:73–84.e16. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin
N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey
R, et al: Safety and immunogenicity of two RNA-based Covid-19
vaccine candidates. N Engl J Med. 383:2439–2450. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim J, Song Y, Park CH and Cho C: Platform
technologies and human cell lines for the production of therapeutic
exosomes. Extracell Vesicles Circ Nucleic Acids. 2:3–17. 2021.
|
|
63
|
van Doremalen N, Lambe T, Spencer A,
Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA,
Bushmaker T, Flaxman A, Ulaszewska M, et al: ChAdOx1 nCoV-19
vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature.
586:578–582. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Song L, Tang S, Han X, Jiang Z, Dong L,
Liu C, Liang X, Dong J, Qiu C, Wang Y, et al: KIBRA controls
exosome secretion via inhibiting the proteasomal degradation of
Rab27a. Nat Commun. 10:16392019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li J, Chen X, Yi J, Liu Y, Li D, Wang J,
Hou D, Jiang X, Zhang J, Wang J, et al: Identification and
characterization of 293T cell-derived exosomes by profiling the
protein, mRNA and MicroRNA components. PLoS One. 11:e01630432016.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Merten OW, Hebben M and Bovolenta C:
Production of lentiviral vectors. Mol Ther Methods Clin Dev.
3:160172016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shen C, Gu M, Song C, Miao L, Hu L, Liang
D and Zheng C: The tumorigenicity diversification in human
embryonic kidney 293 cell line cultured in vitro. Biologicals.
36:263–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
